Hemispherx BioPharma (HEB) Stock Price, News & Analysis

Company Overview

Hemispherx BioPharma, Inc. (NYSE American: HEB) is a clinical‐stage biopharmaceutical company focused on the development and commercialization of immunotherapeutic products. The company’s primary activities center on researching and advancing compounds designed to modulate the immune system in order to treat viral infections, cancer, and other immune‐related disorders. Hemispherx BioPharma’s two lead candidates—Ampligen® (rintatolimod) and Alferon® N Injection—are being investigated for their potential to stimulate innate immune responses and support traditional antiviral and anticancer therapies.

Ampligen®, a toll‐like receptor 3 agonist, has been evaluated in multiple clinical trials for chronic fatigue syndrome, cancer immunotherapy combinations, and emerging viral threats. The compound is designed to broadly activate antiviral defense mechanisms, making it a candidate for both rare diseases and potential pandemic preparedness. Alferon® N Injection, a naturally derived interferon alpha formulation, has been used under limited approval for certain HPV‐related conditions and is under further study for its efficacy against viral and oncological indications.

Founded in 1981 and headquartered in Philadelphia, Pennsylvania, Hemispherx BioPharma operates research laboratories in the United States and maintains strategic collaborations with federal and academic institutions. The company has engaged in partnerships with agencies such as the U.S. Department of Defense and the National Institutes of Health to support preclinical and clinical programs. Through these alliances, Hemispherx aims to leverage government-sponsored research and expedite the development timelines for its immunotherapeutic candidates.

Under the leadership of its President and Chief Executive Officer, the company draws on a management team with extensive experience in biotechnology development and regulatory affairs. Scientific advisors and board members bring expertise in clinical trial design, pharmaceutical manufacturing, and commercialization strategies. As Hemispherx BioPharma advances its clinical pipeline, the organization remains committed to addressing unmet medical needs in immunology and infectious diseases.

Key Stats

• Today's Range: $5.80 to $9.00
• 50-Day Range: $0.09 to $8.38
• 52-Week Range: $1.69 to $14.81
• Volume: 7,639 shs
• Average Volume: 102,599 shs
• Market Capitalization: $16.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

HEB Stock Analysis - Frequently Asked Questions

How have HEB shares performed this year?

Hemispherx BioPharma's stock was trading at $0.2170 at the start of the year. Since then, HEB stock has increased by 2,987.6% and is now trading at $6.70.

How were Hemispherx BioPharma's earnings last quarter?

Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) announced its earnings results on Thursday, August, 15th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, topping analysts' consensus estimates of ($1.70) by $0.63. The specialty pharmaceutical company earned $0.03 million during the quarter.

When did Hemispherx BioPharma's stock split?

Hemispherx BioPharma shares reverse split before market open on Tuesday, June 11th 2019.The 1-44 reverse split was announced on Friday, May 31st 2019. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 10th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of Hemispherx BioPharma?

Shares of HEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Hemispherx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemispherx BioPharma investors own include NewLink Genetics (NLNK), Goodrich Petroleum (GDPMQ), Biocept (BIOC), CTI BioPharma (CTIC), Inovio Pharmaceuticals (INO), Palatin Technologies (PTN) and Ayala Pharmaceuticals (ADXS).

Company Calendar

• Last Earnings: 8/15/2019
• Today: 7/10/2025

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NYSEAMERICAN:HEB
• Previous Symbol: NYSE:HEB
• CIK: 946644
• Web: www.hemispherx.net
• Phone: +1-407-2718516
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,442,000
• Free Float: N/A
• Market Cap: $16.36 million
• Optionable: Not Optionable
• Beta: N/A